Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of purinostat mesylate injection in relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
CTR20233882Phase 2Completed
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co., Ltd.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of purinostat in peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), sponsored by Guizhou Bailing Group Pharmaceutical Co., Ltd.. Started Apr 2024; status: completed.
02
Drugs
purinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on CTR20233882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233882.